UK Medical Cannabis & Vaporisers — A Patient's Guide

Over 34,000 patients are registered on the UK Medical Cannabis Registry.^[1] Broader estimates suggest between 50,000 and 60,000 are actively prescribed.^[2] Almost all prescriptions specify vaporisation as the method of administration — yet most patients receive remarkably little guidance on which device to use, what to expect from the process, or how much the whole thing will actually cost.

This guide covers the prescription pathway from first enquiry to ongoing treatment, with particular attention to the practical questions that clinic websites tend not to answer: real-world costs, device selection, VAT relief, travel considerations, and adverse event reporting. Where data is evolving — and in this field, it evolves quickly — the text says so.

How the UK Got Here

Cannabis-based medicinal products became legal for specialist prescription in the United Kingdom on 1 November 2018. The change followed two high-profile cases involving children with severe epilepsy — Billy Caldwell (then aged 12) and Alfie Dingley (then aged 6) — whose conditions responded to cannabis-derived treatments unavailable through the NHS.^[3] The rescheduling moved cannabis-based medicinal products from Schedule 1 to Schedule 2 of the Misuse of Drugs Regulations 2001, permitting specialist doctors to prescribe them on a named-patient basis.

In the years since, growth has been substantial. Consultations increased by 348% across 2025, and prescription volumes rose 262% compared to 2022.^[2] Two licensed cannabis-based medicines — Sativex (nabiximols) for multiple sclerosis spasticity and Epidyolex (highly purified CBD) for rare epilepsy syndromes — are available through the NHS, accounting for roughly 5,000 community prescriptions in 2023. The remaining tens of thousands of patients access unlicensed cannabis flower and oils through private clinics, a split that has defined the UK medical cannabis landscape since legalisation.

Which Conditions Qualify

There is no fixed list of qualifying conditions. Each case is assessed individually based on clinical evidence, the severity of the condition, and the patient's treatment history.^[4] The general eligibility criteria require that a patient has been diagnosed by a licensed medical professional, has tried at least two conventional treatments without adequate success, is not pregnant, has no history of psychosis or schizophrenia, and is aged 18 or over (patients under 18 require assessment by a paediatric specialist).

Conditions commonly approved through private clinics include chronic pain, epilepsy (particularly Dravet and Lennox-Gastaut syndromes), multiple sclerosis spasticity, post-traumatic stress disorder, Crohn's disease, sleep disorders, inflammatory bowel disease, and cancer-related symptoms including chemotherapy-induced nausea.^{[4, 5]} The emphasis on "two prior treatments" is worth noting — this does not necessarily mean two failed medications. Some clinics accept evidence that conventional treatments caused intolerable side effects or were otherwise unsuitable.

How to Get a Prescription

The NHS Route

NHS access remains extremely limited. NICE guideline NG144, published in November 2019, restricts NHS prescribing to four specific circumstances: Dravet syndrome, Lennox-Gastaut syndrome, multiple sclerosis spasticity (Sativex), and chemotherapy-induced nausea and vomiting (nabilone).^[6] All require specialist referral. Unlicensed cannabis-based products can only be prescribed by doctors on the GMC specialist register, on a named-patient basis, and only when licensed treatments have been exhausted. In practice, roughly 99% of UK medical cannabis patients access their prescriptions privately.^[2]

The Private Clinic Route

The private prescription process is more straightforward than many patients expect. No GP referral is needed — patients can self-refer directly to any registered private cannabis clinic. The typical pathway involves four steps.

First, the patient gathers relevant medical records. Most clinics accept a Summary Care Record (available from the GP), hospital letters, or specialist reports. Some clinics will request records directly from the GP with the patient's consent.

Second, an initial consultation takes place, almost always by video call, with a GMC-registered specialist doctor. This typically lasts 20–30 minutes and covers medical history, previous treatments, current symptoms, and suitability for cannabis-based treatment.

Third, if the clinician considers the patient eligible, a prescription is issued. Prescriptions specify the product (flower strain, THC/CBD ratio, and form), the dose, and the method of administration — which in the overwhelming majority of cases is vaporisation.

Fourth, the prescribed medication is dispensed by the clinic's associated pharmacy and delivered to the patient's home by secure courier. First prescriptions typically arrive within 3–7 working days.

Comparing UK Cannabis Clinics

The private clinic market has matured considerably since 2018, with several established providers now operating nationally. The table below summarises the major clinics as of April 2026. Prices change frequently — verify directly before booking.

This guide does not recommend any single clinic. The best choice depends on the patient's condition, location, budget, and personal preferences. Cannabis Access Clinics (cannabisaccessclinics.co.uk) publishes verified patient reviews and comparative data that may help with this decision.^[7]

What It Actually Costs

The cost of medical cannabis in the UK breaks down into three components: consultation fees, medication, and (optionally) subscription plans. The figures below were verified in April 2026 but should be checked against current clinic pricing before making decisions.

Consultations

Initial consultations range from £49 to £200, with most major clinics charging between £50 and £100. Releaf's initial appointment, for example, costs £99.99. Follow-up and repeat prescription appointments are considerably cheaper — typically around £19.99 on a pay-as-you-go basis.^[8] Some clinics offer a money-back guarantee if the clinician determines the patient is not suitable for cannabis-based treatment.

Medication

Prescribed cannabis flower currently costs between £6 and £9 per gram at most clinics, with premium strains reaching up to £25 per gram.^{[8, 9]} Monthly prescriptions typically range from 10g to 60g depending on the condition, the prescribed dose, and the frequency of use. This translates to a monthly medication cost of roughly £60 to £540 — a wide range that reflects the significant variation in individual treatment plans.

Subscription Plans

Several clinics now offer subscription models that reduce per-appointment and per-gram costs in exchange for a monthly fee. Releaf+, for instance, charges from £39.99 per month and includes free consultations, free delivery, and flower from £7.99 per gram.^[8] Other clinics offer pay-as-you-go models with appointment fees as low as £5–£29.

The Total Picture

A patient on a moderate prescription of 30g per month through a subscription plan might expect to pay roughly £240–£340 per month in total (medication plus subscription fee). Without a subscription, the same patient could face £270–£400 per month when factoring in individual appointment charges. These are indicative figures — actual costs depend on the clinic, the product, and the dosing regimen.

VAT Exemption on Medical Vaporisers

A provision that many patients are unaware of: individuals with a chronic illness or disability can claim VAT exemption on the purchase of qualifying medical devices, including vaporisers used for prescribed cannabis.^[10] The patient (or a family member or carer acting on their behalf) completes a VAT exemption declaration confirming they are "chronically sick or disabled" as defined under VAT legislation. The item must be one that directly contributes to the patient's medical care or has been prescribed by a qualified professional.

This represents a 20% saving on what are often expensive devices. The VAT Disabled Reliefs Helpline (0300 123 1073) can provide further guidance on eligibility. Several online retailers, including vaporiser specialists, already offer VAT exemption at checkout for qualifying customers.

Cancard: What It Is and What It Is Not

Cancard is a voluntary identification card launched in November 2020 by Drug Science, the independent scientific body chaired by Professor David Nutt.^[11] The card identifies the holder as someone whose medical condition would likely qualify for a cannabis prescription, and is intended to provide context during interactions with police — particularly during stop-and-search encounters.

Obtaining a Cancard requires medical evidence of a qualifying condition. Many patients use it as an interim measure while waiting for a formal prescription or as supplementary identification alongside an existing prescription.

It is important to be precise about what Cancard does and does not provide. Cancard is not officially endorsed by the Department of Health and Social Care, the Home Office, or any UK government body. It is not a legal licence to possess or use cannabis. It is not a prescription. A Cancard holder who is found in possession of cannabis without a valid prescription is, in law, in possession of a controlled substance. Police officers may choose to exercise discretion when presented with a Cancard, but they are under no legal obligation to do so. The card does not override the Misuse of Drugs Act 1971.^[11]

The most accurate way to think of Cancard is as a tool that may encourage police discretion — not a replacement for a prescription. For patients who are in the process of obtaining a prescription, or who cannot currently afford one, it may offer a degree of practical reassurance. It should not be relied upon as legal protection.

Which Devices Do Clinics Recommend?

Almost all UK cannabis clinics recommend vaporisation as the preferred method of administration. Specific device recommendations, however, are rarely published on clinic websites and vary between clinicians.^[7]

The only dry herb vaporisers with published medical device certification are manufactured by Storz & Bickel under the VAPORMED brand: the Volcano Medic 2 (desktop) and the Mighty+ Medic (portable). These devices hold ISO 13485 certification and comply with DIN EN 60601 standards for medical electrical equipment.^[12] For patients who need validated, consistent dosing — and particularly for those whose treatment records may need to demonstrate precise administration — certified devices offer documented assurance that non-certified devices do not.

In practice, however, patients use a far broader range of devices than the medically certified options. Many clinicians are pragmatic: the priority is that the patient vaporises rather than smokes, and any quality vaporiser from a reputable manufacturer achieves this. Dosing capsules — pre-loadable chambers that hold a measured quantity of ground flower — are increasingly popular among medical users for the consistency and convenience they provide. For a detailed examination of what medical device certification means and how it differs from the marketing term "medical grade," see [Medical Grade vs Medical Certified Vaporisers — What's the Difference?].

Travelling with Prescribed Cannabis

Within the UK

Travelling within the United Kingdom with prescribed cannabis is legal. Patients should carry a printed copy of their prescription and keep medication in its original packaging.^[13] A letter from the prescribing clinician, while not strictly required for domestic travel, provides additional documentation in case of questions from police or transport security.

International Travel

Travelling abroad with prescribed cannabis requires careful preparation and varies significantly by destination. For trips involving more than three months' supply, an export licence from the Home Office is required — applications should be submitted at least 10 working days before departure.^[14] For shorter trips, a letter from the prescribing clinician detailing the medicines being carried is generally sufficient, though requirements vary by country.

Some countries — including Germany, the Netherlands, and parts of Canada — have frameworks for recognising foreign cannabis prescriptions.^[13] Others maintain strict zero-tolerance policies regardless of prescription status. Singapore, Japan, and the United Arab Emirates impose severe penalties for cannabis possession even when accompanied by valid medical documentation.^[13] Patients should always research the specific laws of their destination country before travelling and should consider contacting the relevant embassy or consulate for current guidance.

Dosing and Technique for Medical Users

Medical vaporisation differs from recreational use in one important respect: consistency matters. Patients are typically prescribed specific doses — often expressed as a number of inhalations at a defined temperature — and the goal is to reproduce the same therapeutic effect each session.

Several practical factors affect dosing consistency. The grind should be even and medium-fine. The chamber should be packed consistently — neither too tight (which restricts airflow) nor too loose (which produces thin, inconsistent vapour). Temperature selection matters: lower temperatures (around 170–185°C / 338–365°F) tend to produce lighter, more cerebral effects dominated by THC and monoterpenes, while higher temperatures (around 195–210°C / 383–410°F) extract a fuller range of cannabinoids and sesquiterpenes.^[15] Dosing capsules simplify this process considerably by ensuring the same quantity is loaded each time.

For patients new to vaporisation, the general clinical advice is to start at a lower temperature, take one or two inhalations, and wait 10–15 minutes before taking more. The onset of inhaled cannabinoids is rapid — typically within 2–5 minutes — which allows for cautious titration that is not possible with oral administration (where onset can take 60–120 minutes).^[16] For a detailed explanation of why inhaled cannabis produces faster and more predictable effects than oral consumption, see [The Bioavailability of Vaporising vs Smoking].

Project Twenty21: The UK Evidence Base

Drug Science's Project Twenty21 was the United Kingdom's largest observational study of medical cannabis, running from 2020 to 2024.^[17] The study enrolled 2,833 patients at treatment entry, with 1,410 completing the three-month follow-up. Conditions studied included anxiety, chronic pain, and post-traumatic stress disorder.

Key outcomes included improvements in general health and quality of life, reduction in condition-specific symptoms, and — notably — reduced opioid use among chronic pain patients.^{[17, 18]} While the study was observational rather than a randomised controlled trial (and therefore cannot establish causation), its scale and UK-specific patient population make it one of the most relevant data points in the current evidence base. Drug Science continues to use the data to advocate for NHS funding and broader access.

PLEA and Patient Advocacy

The Patient-Led Engagement for Access (PLEA) community is a patient-led advocacy group working to address the inequalities that still characterise UK medical cannabis access.^[19] Their focus areas include challenging misinformation and stigma, addressing financial barriers to access, highlighting geographical inconsistencies in prescribing, and advocating for integration of cannabis-based treatments within mainstream NHS healthcare. PLEA collaborates with Drug Science and operates from a harm-reduction perspective. For patients navigating the system for the first time, their resources and community forums can provide practical guidance alongside the clinical pathway.

Reporting Adverse Effects: The Yellow Card Scheme

If you experience adverse effects from a vaporiser device or prescribed cannabis medication, you can report them to the MHRA's Yellow Card scheme at yellowcard.mhra.gov.uk. Reports from patients and carers are actively encouraged and contribute directly to UK pharmacovigilance data. Yellow Card reports help identify safety signals that may not emerge during clinical trials and are an important part of the broader patient safety infrastructure.^[20]

Reporting is straightforward, takes approximately 10 minutes, and can be completed online or via the Yellow Card app. Reports can be made by the patient, a family member, or a carer. All reports are reviewed by the MHRA's safety team.